Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Mitral Regurgitation
← New Search

Mitral Regurgitation

Educational clinical summary of Mitral Regurgitation for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This medical reference is for informational purposes only and is not intended as medical advice. Clinical decisions must be made by qualified healthcare professionals based on individual patient circumstances, current medical guidelines, and clinical judgment. Always consult with a physician or other qualified healthcare provider for any health concerns or before making any decisions related to patient care.

Overview

  • Definition: Mitral regurgitation (MR) is a valvular heart disease characterized by an incompetent mitral valve that allows blood to flow backward from the left ventricle (LV) into the left atrium (LA) during ventricular systole. This retrograde flow leads to volume overload of both the LA and LV.

  • Epidemiology:

    • MR is the most common form of valvular heart disease after aortic stenosis.
    • Prevalence increases with age, affecting approximately 2% of the general population and up to 10% of individuals aged 75 years and older.
    • Degenerative MR (primary MR) is the most common cause in developed countries.
    • Functional MR (secondary MR) is common in patients with heart failure due to LV dysfunction.
    • Rheumatic MR remains prevalent in developing countries.

  • Classification:

    • By Etiology (Carpentier's Classification / Primary vs. Secondary):
      • Primary (Organic/Degenerative) MR: Caused by intrinsic abnormalities of the mitral valve apparatus (leaflets, chordae tendineae, papillary muscles, annulus).
        • Degenerative/Myxomatous MR: Most common cause in developed countries. Includes Barlow's disease (diffuse myxomatous degeneration, leaflet prolapse, chordal elongation) and fibroelastic deficiency (focal chordal rupture, thinner leaflets, less diffuse involvement).
        • Rheumatic Heart Disease: Leading cause globally, due to chronic inflammation causing leaflet thickening, commissural fusion, chordal shortening.
        • Endocarditis: Destructive lesions (vegetations, perforations, chordal rupture).
        • Ischemic MR (Primary Type): Infarction directly involving papillary muscle, leading to rupture or dysfunction. (Note: this is rare, usually ischemic MR is secondary).
        • Connective Tissue Disorders: Marfan syndrome, Ehlers-Danlos syndrome.
        • Congenital Anomalies: Cleft mitral valve, parachute mitral valve.
        • Trauma.
      • Secondary (Functional/Ischemic) MR: Occurs in a structurally normal mitral valve, but leaflet coaptation is impaired due to altered LV geometry or function.
        • Ischemic MR: Due to LV remodeling and papillary muscle displacement after myocardial infarction (MI), causing leaflet tethering.
        • Non-Ischemic Dilated Cardiomyopathy: Global LV enlargement and dysfunction leading to annular dilation and papillary muscle displacement.
        • Hypertrophic Cardiomyopathy: Systolic anterior motion (SAM) of the mitral leaflet due to septal hypertrophy.
    • By Acuity:
      • Acute MR: Sudden onset (e.g., papillary muscle rupture from MI, endocarditis with chordal rupture). Presents as cardiogenic shock/acute pulmonary edema.
      • Chronic MR: Develops gradually, allowing compensatory mechanisms (LA/LV dilation). Patients may be asymptomatic for years.
    • By Severity:
      • Mild MR: Small regurgitant volume.
      • Moderate MR: Intermediate regurgitant volume.
      • Severe MR: Large regurgitant volume causing significant hemodynamic burden.
      • Quantified by Echocardiography:
        • Regurgitant Volume (RVol): Mild < 30 mL/beat, Moderate 30-44 mL/beat, Severe ≥ 45 mL/beat.
        • Effective Regurgitant Orifice Area (EROA): Mild < 0.20 cm², Moderate 0.20-0.29 cm², Severe ≥ 0.30 cm². (Note: for secondary MR, severe is often defined as EROA ≥ 0.20 cm² due to different prognostics).
        • Regurgitant Fraction (RF): Mild < 30%, Moderate 30-49%, Severe ≥ 50%.

Pathophysiology

  • Mechanism:

    • Normally, the mitral valve leaflets (anterior and posterior) coapt (close) tightly during ventricular systole, preventing blood flow back into the left atrium. This closure is facilitated by the chordae tendineae, which connect the leaflets to the papillary muscles, preventing prolapse. The mitral annulus provides a stable base.
    • In MR, failure of complete leaflet coaptation leads to regurgitation.
    • Primary MR: Direct structural damage to the valve components. For example, in degenerative MR, myxomatous degeneration weakens the leaflets and chordae, leading to elongation, rupture, or prolapse. This creates a coaptation defect.
    • Secondary MR: The valve structure is normal, but its function is impaired due to changes in LV geometry.
      • LV Remodeling: In dilated cardiomyopathy (ischemic or non-ischemic), the LV dilates, displacing the papillary muscles laterally and posteriorly. This pulls the chordae tendineae and tethers the mitral leaflets, preventing complete closure (leaflet tethering). The annulus may also dilate.
      • Annular Dilation: Significant LA enlargement or LV dilation can stretch the mitral annulus, widening the orifice and preventing leaflet coaptation.
      • LV Dysfunction: The reduced LV contractility in heart failure also contributes to impaired valve closure.
    • Hemodynamic Consequences: The regurgitant volume re-enters the LA, leading to:
      • LA Volume Overload: Increases LA pressure, potentially leading to pulmonary hypertension and atrial fibrillation.
      • LV Volume Overload: The LV receives both systemic venous return and the regurgitant volume from the LA, leading to increased preload.
      • Compensatory Mechanisms (Chronic MR): LA and LV gradually dilate and hypertrophy to accommodate the increased volume and maintain forward stroke volume. This compensation can maintain an asymptomatic state for years.
      • Decompensation: Eventually, chronic volume overload leads to progressive LV dysfunction (reduced ejection fraction), worsening MR, rising pulmonary pressures, and symptoms of heart failure.

  • Risk Factors:

    • Primary MR:
      • Age (degenerative MR)
      • Rheumatic fever (historical/geographical)
      • Infective endocarditis
      • Myocardial infarction (papillary muscle rupture/dysfunction - acute)
      • Connective tissue disorders (e.g., Marfan, Ehlers-Danlos)
      • Hypertrophic obstructive cardiomyopathy (HOCM)
    • Secondary MR:
      • Coronary artery disease (CAD) with myocardial infarction or ischemia
      • Dilated cardiomyopathy (ischemic or non-ischemic)
      • Hypertension (contributes to LV hypertrophy and dysfunction)
      • Diabetes
      • Valvular heart disease (e.g., aortic stenosis leading to LVH)

  • Protective Factors:

    • Primary Prevention:
      • Prevention of rheumatic fever through prompt treatment of streptococcal pharyngitis (antibiotics).
      • Prevention of infective endocarditis (good dental hygiene, appropriate antibiotic prophylaxis for high-risk individuals).
      • Management of cardiovascular risk factors (hypertension, hyperlipidemia, diabetes) to prevent CAD and MI, which can lead to secondary MR.
    • Secondary Prevention:
      • Early diagnosis and optimal medical management of heart failure to prevent/reduce secondary MR.
      • Adherence to guideline-directed medical therapy (GDMT) for heart failure.

Clinical Presentation

Signs and Symptoms

  • Cardinal Features: Symptoms often arise from the compensatory mechanisms becoming overwhelmed, leading to elevated left-sided filling pressures and reduced forward cardiac output.

    • Dyspnea: Exertional dyspnea is often the first symptom, progressing to orthopnea and paroxysmal nocturnal dyspnea (PND). This is due to pulmonary venous congestion.
    • Fatigue/Weakness: Due to reduced forward cardiac output, especially with exertion.
    • Palpitations: Commonly due to atrial fibrillation, which can be precipitated by LA enlargement.
    • Edema: Peripheral edema, ascites, hepatomegaly in advanced cases due to right heart failure secondary to severe pulmonary hypertension.

  • Early Signs (Chronic MR):

    • Often asymptomatic for many years, especially in moderate or severe chronic MR with compensated LV function.
    • Subtle exertional dyspnea or reduced exercise tolerance.
    • Mild fatigue.

  • Advanced Signs (Chronic MR):

    • Dyspnea at rest, orthopnea, PND.
    • Signs of right heart failure: peripheral edema, jugular venous distention (JVD), hepatomegaly, ascites.
    • Cachexia (cardiac cachexia).
    • Symptoms of low cardiac output: dizziness, presyncope, renal impairment.

  • Atypical Presentations:

    • Acute MR: Presents suddenly with severe dyspnea, acute pulmonary edema, and/or cardiogenic shock, often without prior symptoms. Signs of chronic compensation (LA/LV dilation) may be absent.
    • Chest Pain: In patients with ischemic MR or severe pulmonary hypertension.
    • Asymptomatic Severe MR: Patients may have severe MR and significant LV remodeling without symptoms, especially in primary MR. Regular monitoring is crucial for these patients.

Physical Examination

  • General Inspection:

    • Signs of heart failure: Tachypnea, use of accessory muscles, JVD, peripheral edema, cyanosis.
    • Pallor (anemia or low cardiac output).
    • Evidence of underlying cause: Marfanoid habitus, signs of infective endocarditis (Janeway lesions, Osler's nodes, Roth spots).

  • Palpation:

    • Apex Beat: Displaced laterally and inferiorly (volume overload), diffuse and hyperdynamic (left ventricular heave).
    • Thrill: A palpable systolic thrill may be present at the apex, indicating severe MR.

  • Auscultation (Key to Diagnosis):

    • S1 (First Heart Sound): Often diminished or absent due to incomplete mitral valve closure.
    • S2 (Second Heart Sound): May have paradoxical splitting if severe MR causes prolonged LV ejection. The pulmonic component (P2) may be accentuated if pulmonary hypertension is present.
    • S3 (Third Heart Sound): Common in severe MR, especially with LV dysfunction, indicating rapid early diastolic filling of a dilated and volume-overloaded ventricle. A "flow murmur" across the mitral valve may also be heard in mid-diastole.
    • Murmur of MR:
      • Character: High-pitched, holosystolic (pansystolic) murmur, meaning it begins with S1 and extends through S2.
      • Location: Best heard at the apex (mitral area).
      • Radiation: Typically radiates to the left axilla or left infrascapular area. In anterior leaflet prolapse with a posteriorly directed jet, it may radiate to the left axilla. In posterior leaflet prolapse with an anteriorly directed jet, it may radiate to the base of the heart (mimicking aortic stenosis).
      • Intensity: Varies with severity. A loud murmur does not always equate to severe MR, especially in acute MR where a rapid rise in LA pressure can diminish the gradient.
      • Maneuvers:
        • Increases intensity: Handgrip (increases afterload), squatting (increases preload and afterload), expiration.
        • Decreases intensity: Valsalva maneuver (decreases preload).

Diagnostic Approach

History Taking

  • Key Questions:

    • Symptoms: Onset, duration, progression, and severity of dyspnea (exertional, orthopnea, PND), fatigue, palpitations, chest pain, edema. Quantify exercise tolerance (e.g., stairs climbed, blocks walked).
    • Acuity: Was the onset sudden (acute MR) or gradual (chronic MR)?
    • Past Medical History: History of rheumatic fever, infective endocarditis, myocardial infarction, heart failure, hypertension, atrial fibrillation, connective tissue disorders, hypertrophic cardiomyopathy, renal disease.
    • Medications: Current medications, especially those for heart failure.
    • Risk Factors: Lifestyle (smoking, alcohol, illicit drug use).
    • Family History: Valvular disease, cardiomyopathy.

  • Red Flags:

    • Sudden onset of severe dyspnea, orthopnea, or PND: Suggests acute MR and acute pulmonary edema.
    • Signs of cardiogenic shock: Hypotension, altered mental status, oliguria, cool extremities.
    • New-onset or rapidly worsening heart failure symptoms: Indicate LV decompensation.
    • Febrile illness with new murmur or worsening symptoms: Suspect infective endocarditis.

Laboratory Tests

  • First-Line:

    • Complete Blood Count (CBC): To assess for anemia (can exacerbate symptoms) or leukocytosis (infection, endocarditis).
    • Basic Metabolic Panel (BMP): Assess renal function (BUN, creatinine) and electrolytes, especially if diuretics are used.
    • Brain Natriuretic Peptide (BNP) or N-terminal pro-BNP (NT-proBNP): Elevated levels indicate myocardial stretch and correlate with symptom severity, LV dysfunction, and prognosis in heart failure. Helpful for assessing severity and monitoring response to therapy.
    • Liver Function Tests (LFTs): Assess for hepatic congestion in right heart failure.
    • Thyroid-Stimulating Hormone (TSH): Rule out thyroid dysfunction contributing to palpitations or heart failure.

  • Confirmatory: No specific laboratory test directly confirms MR; diagnosis relies on imaging. Labs help assess the severity of impact and comorbidities.

  • Monitoring:

    • Serial BNP/NT-proBNP to monitor disease progression and response to medical therapy.
    • Renal function, electrolytes, and liver function during long-term management, especially with diuretic or GDMT.

Imaging

  • Recommended (Gold Standard):

    • Transthoracic Echocardiography (TTE):
      • Diagnostic: Confirms the presence of MR, quantifies severity, identifies the mechanism (primary vs. secondary), and assesses the overall cardiac structure and function.
      • Severity Assessment (Quantitative):
        • Doppler Color Flow: Qualitatively assesses jet size and shape.
        • PISA (Proximal Isovelocity Surface Area) Method: Calculates Effective Regurgitant Orifice Area (EROA) and Regurgitant Volume (RVol).
          • Severe Primary MR: EROA ≥ 0.40 cm², RVol ≥ 60 mL/beat.
          • Severe Secondary MR: EROA ≥ 0.20 cm², RVol ≥ 30 mL/beat (lower thresholds due to worse prognosis at smaller RVol in dilated hearts).
        • Regurgitant Fraction (RF): Ratio of RVol to total LV stroke volume. Severe ≥ 50% for primary MR, ≥ 30% for secondary MR.
        • Vena Contracta Width: Narrowest portion of the MR jet: Mild < 0.3 cm, Severe ≥ 0.7 cm (primary MR).
      • Structural Assessment: Evaluates mitral valve leaflets, chordae, annulus, papillary muscles for specific pathologies (e.g., prolapse, flail leaflet, calcification, vegetation, restricted motion).
      • Chamber Assessment: Measures LA size (LA volume index >34 mL/m²), LV end-diastolic and end-systolic dimensions/volumes, LV ejection fraction (LVEF). Important for surgical timing (e.g., LVEF <60% or LV end-systolic diameter (LVESD) >40 mm in asymptomatic primary MR).
      • Pulmonary Artery Pressure (PAP): Estimated from tricuspid regurgitation jet, important for prognosis and surgical timing.
      • Evaluation of RV function: Due to the impact of pulmonary hypertension.

  • Advanced:

    • Transesophageal Echocardiography (TEE):
      • Provides superior image quality of the mitral valve structure due to closer proximity.
      • Indications: When TTE is inconclusive, for detailed anatomical assessment (e.g., suitability for valve repair), to evaluate for endocarditis, or during surgical/transcatheter interventions. Crucial for surgical planning.
    • Cardiac Magnetic Resonance Imaging (CMR):
      • Indications: When echocardiography is suboptimal or for highly accurate quantification of LV volumes, LVEF, and regurgitant volume/fraction, especially in complex cases or when discordant with clinical findings. Can also assess for myocardial fibrosis (late gadolinium enhancement).
    • Cardiac Computed Tomography (CT):
      • Indications: Provides detailed anatomical assessment of the mitral annulus, subvalvular apparatus, and surrounding structures. Useful for planning transcatheter mitral valve interventions, evaluating calcification, and assessing coronary anatomy.
    • Exercise Echocardiography:
      • Indications: For symptomatic assessment in patients with discordant symptoms and resting echo findings, or to unmask exercise-induced pulmonary hypertension in asymptomatic severe MR. Can quantify dynamic changes in MR severity and LV/LA pressures.
    • Coronary Angiography:
      • Indications: Routinely performed prior to mitral valve surgery to rule out significant coronary artery disease that may require concomitant bypass grafting.

Management

Management of MR depends crucially on its etiology (primary vs. secondary), acuity (acute vs. chronic), and severity, as well as the patient's symptoms and LV function.

Acute Management (Acute Severe MR)

Acute severe MR is a medical emergency requiring prompt stabilization and often urgent surgical intervention.

  • Immediate Interventions: Aimed at reducing pulmonary congestion and improving forward cardiac output.

    • Preload Reduction:
      • Intravenous Diuretics: Furosemide 40-80 mg IV, titrated rapidly to reduce pulmonary edema.
      • Venodilators: Nitroglycerin IV infusion (e.g., 10-200 mcg/min) to reduce preload and afterload, improving pulmonary congestion.
    • Afterload Reduction:
      • Vasodilators: Sodium nitroprusside IV infusion (e.g., 0.5-10 mcg/kg/min) can be very effective by decreasing systemic vascular resistance, thereby increasing forward stroke volume and reducing regurgitant volume. Caution: Avoid if patient is hypotensive.
    • Inotropic Support: If cardiogenic shock is present despite vasodilators (e.g., dobutamine 2.5-20 mcg/kg/min) to improve contractility and cardiac output.
    • Mechanical Circulatory Support: Intra-aortic balloon pump (IABP) can be used to reduce afterload and support LV function as a bridge to definitive treatment.

  • Stabilization:

    • Respiratory Support: Oxygen supplementation, non-invasive positive pressure ventilation (NIPPV) or invasive mechanical ventilation for acute respiratory failure.
    • Rhythm Control: Address arrhythmias (e.g., atrial fibrillation) that can worsen hemodynamics.
    • Search for Etiology: Promptly identify the cause (e.g., MI, endocarditis) to guide definitive treatment.

  • Emergency Treatment:

    • Urgent Mitral Valve Surgery (Repair or Replacement): The definitive treatment for acute severe MR causing hemodynamic instability, cardiogenic shock, or refractory pulmonary edema. This is particularly true for acute primary MR (e.g., papillary muscle rupture, severe endocarditis).

Chronic Management

Pharmacological Management

  • Primary (Degenerative) MR:

    • No specific medical therapy to prevent or reverse MR progression.
    • Management is primarily supportive:
      • Diuretics: For symptom relief of volume overload (dyspnea, edema).
      • Vasodilators: ACE inhibitors/ARBs may be considered if hypertension is present or to reduce afterload in symptomatic patients unsuitable for surgery, but no strong evidence for routine use in asymptomatic patients with preserved LV function.
      • Beta-blockers: If concomitant CAD or heart rate control needed.
      • Atrial Fibrillation Management: Rate or rhythm control, anticoagulation as per guidelines (CHA2DS2-VASc score).
    • Endocarditis Prophylaxis: Recommended only for high-risk patients (e.g., prosthetic valve, previous endocarditis, specific congenital heart disease) undergoing dental procedures involving manipulation of gingival tissue or periapical region of teeth, or perforation of oral mucosa. Not for isolated MR.

  • Secondary (Functional) MR:

    • Optimal Guideline-Directed Medical Therapy (GDMT) for Heart Failure is the Cornerstone: Addressing the underlying LV dysfunction is key to reducing MR severity.
      • ACE Inhibitors / Angiotensin Receptor Blockers (ARBs) / Angiotensin Receptor-Neprilysin Inhibitors (ARNIs): (e.g., Sacubitril/Valsartan) Improve LV function, reduce LV remodeling, and may decrease MR severity.
      • Beta-Blockers: (e.g., Carvedilol, Metoprolol succinate, Bisoprolol) Improve LV function, reduce heart rate, and can lead to reverse remodeling.
      • Mineralocorticoid Receptor Antagonists (MRAs): (e.g., Spironolactone, Eplerenone) Reduce fibrosis, improve LV function.
      • Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: (e.g., Dapagliflozin, Empagliflozin) Improve HF outcomes regardless of diabetes status.
      • Diuretics: For symptom relief of congestion.
    • Cardiac Resynchronization Therapy (CRT): In patients with reduced LVEF and wide QRS, CRT can improve LV synchrony, reduce LV size, and significantly reduce secondary MR severity.

Non-Pharmacological Management

  • Lifestyle Modifications:
    • Sodium restriction (<2g/day) for symptom management and prevention of fluid retention.
    • Regular physical activity (as tolerated, guided by symptoms and LV function).
    • Weight management.
    • Smoking cessation, alcohol moderation.
  • Patient Education: Importance of symptom monitoring, medication adherence, and follow-up.

Monitoring (Chronic MR)

  • Clinical Follow-up: Regular assessment of symptoms, functional status, and physical exam findings.
  • Echocardiography:
    • Asymptomatic severe primary MR with preserved LV function: Every 6-12 months.
    • Moderate MR: Every 1-2 years.
    • Mild MR: Every 3-5 years.
    • More frequent if symptoms change, LV function deteriorates, or new complications arise.
  • Biomarkers: Serial BNP/NT-proBNP may be useful to track disease progression and guide therapy.

Treatment Algorithms (Intervention Thresholds)

Intervention (surgery or transcatheter) for chronic severe MR is guided by symptom status, LV function, and other cardiac parameters.

Primary Chronic Severe MR

Class I Indications for Intervention (ACC/AHA 2020/2021, ESC 2022): 1. Symptomatic severe primary MR: For all symptomatic patients (NYHA Class II, III, or IV) with LVEF >30%. (Surgical repair is preferred). 2. Asymptomatic severe primary MR with LV dysfunction: LVEF <60% and/or LV end-systolic diameter (LVESD) ≥40 mm. * Rationale: These thresholds indicate early LV decompensation, and intervention at this stage can prevent irreversible LV damage. 3. Asymptomatic severe primary MR with preserved LV function (LVEF ≥60% and LVESD <40 mm) but with specific indications: * New-onset atrial fibrillation: Attributable to MR (due to LA enlargement). * Pulmonary Hypertension: Systolic pulmonary artery pressure (sPAP) >50 mmHg at rest or >60 mmHg with exercise. * Mitral valve repair with high likelihood of success and low surgical risk: In experienced centers (surgical mortality <1%). This is particularly for patients with flail leaflet.

Considerations for Transcatheter Mitral Valve Edge-to-Edge Repair (TMVr, e.g., MitraClip): * Indication (Class IIb): For symptomatic severe primary MR in patients who are considered high-risk for surgery by a heart team, or who have contraindications to surgery. This is generally considered when surgical risk is prohibitive.

Secondary Chronic Severe MR

The focus is on optimizing GDMT for heart failure. Intervention is generally considered when GDMT has failed.

Class I Indications for Intervention (ACC/AHA 2020/2021, ESC 2022): 1. Optimal GDMT (including CRT if indicated) for heart failure has failed AND: * Symptomatic severe secondary MR (NYHA Class II, III, or IV). * LVEF 20-50%. * Favorable anatomy for TMVr. * Rationale: Based on trials like COAPT and MITRA-FR, TMVr improves outcomes (mortality, HF hospitalizations) in selected patients with severe secondary MR and HF who remain symptomatic despite optimal GDMT. This is usually the first-line interventional therapy.

  1. Surgical Mitral Valve Replacement (MVR):
    • Indications (Class IIb): For severe secondary MR in patients undergoing concomitant CABG, if there is persistent severe MR after revascularization, or in selected patients where TMVr is not feasible and surgical risk is acceptable. MVR for isolated secondary MR is generally not recommended unless there's a strong surgical indication, as it does not typically improve survival and is associated with higher operative risk.

Surgical Options

  • Mitral Valve Repair (MVRp):
    • Preferred over replacement whenever feasible, especially in primary MR, due to better preservation of LV function, lower risk of endocarditis, and avoidance of anticoagulation for prosthetic valves.
    • Techniques: Annuloplasty (ring insertion), leaflet resection, chordal repair/replacement (neo-chordae).
  • Mitral Valve Replacement (MVR):
    • Indications: When repair is not feasible (e.g., extensive leaflet destruction, severe calcification, active endocarditis) or for certain secondary MR cases.
    • Types: Mechanical prosthetic valves (require lifelong anticoagulation) or bioprosthetic valves (less durable, no lifelong anticoagulation).

Complications

  • Common:

    • Heart Failure: Progressive symptoms of dyspnea, fatigue, fluid retention due to chronic volume overload and eventual LV dysfunction.
    • Atrial Fibrillation (AF): Due to chronic LA dilation and increased LA pressure. AF itself can worsen MR by reducing ventricular filling time and causing asynchronous LV contraction.
    • Pulmonary Hypertension: Chronic elevation of LA pressure leads to increased pulmonary venous pressure, eventually causing pulmonary arterial hypertension and RV dysfunction.

  • Serious:

    • Acute Pulmonary Edema: A common presentation of acute MR, or acute decompensation of chronic MR.
    • Cardiogenic Shock: Especially in acute severe MR.
    • Infective Endocarditis: Damaged valves are more susceptible to infection.
    • Sudden Cardiac Death: Though rare, risk increases with severe LV dysfunction, pulmonary hypertension, and complex arrhythmias.

  • Long-term:

    • Irreversible Left Ventricular Dysfunction: Prolonged volume overload can lead to myocardial fibrosis and systolic dysfunction, even after successful MR correction.
    • Right Heart Failure: Due to chronic pulmonary hypertension.
    • Recurrence of MR: Can occur after repair, particularly with annuloplasty rings that are too small or with progressive underlying disease.
    • Thromboembolism: Increased risk with AF and/or prosthetic valves.

Prognosis

  • Factors Affecting Outcome:

    • Severity of MR: Worse prognosis with more severe regurgitation.
    • Left Ventricular (LV) Function: LVEF and LV dimensions (LVESD) are the strongest prognostic indicators. Worsening LVEF (<60%) and increasing LVESD (>40mm) in asymptomatic primary MR indicate worse outcomes. In secondary MR, the underlying LV dysfunction is key.
    • Symptom Status: Symptomatic patients have a worse prognosis than asymptomatic ones, necessitating earlier intervention.
    • Pulmonary Hypertension: Presence and severity of PH are adverse prognostic indicators.
    • Atrial Fibrillation: Worsens prognosis due to increased risk of stroke and impaired hemodynamics.
    • Etiology of MR: Primary MR generally has a better prognosis after successful repair than secondary MR, where the underlying myocardial disease remains.
    • Age and Comorbidities: Older age and significant comorbidities negatively impact prognosis.

  • Survival:

    • Asymptomatic severe primary MR with preserved LV function has an excellent prognosis, often remaining stable for many years. However, once symptoms develop or LV dysfunction occurs, the 5-year survival significantly drops without intervention.
    • Acute severe MR has a very high mortality rate without urgent intervention.
    • Secondary MR prognosis is largely determined by the severity of the underlying LV dysfunction and heart failure, and its response to GDMT.

  • Quality of Life: Significantly impaired by symptoms of heart failure. Successful intervention, particularly valve repair, can dramatically improve symptoms, functional capacity, and quality of life.

Prevention

  • Primary Prevention: Aimed at preventing the initial occurrence of MR.

    • Prevention of Rheumatic Fever: Prompt and adequate antibiotic treatment of Group A streptococcal pharyngitis (e.g., Penicillin) to prevent acute rheumatic fever and subsequent rheumatic heart disease.
    • Prevention of Infective Endocarditis: Good oral hygiene, prudent use of antibiotic prophylaxis for high-risk individuals undergoing specific dental procedures (as per current guidelines).
    • Management of Cardiovascular Risk Factors: Strict control of hypertension, diabetes, hyperlipidemia, and prevention of coronary artery disease to reduce the risk of myocardial infarction and subsequent ischemic MR.

  • Secondary Prevention: Early detection and intervention in individuals with existing risk factors or mild/moderate MR to prevent progression.

    • Regular follow-up and echocardiographic surveillance for patients with known risk factors or mild/moderate MR.
    • Optimal medical therapy for heart failure in patients with LV dysfunction to prevent or mitigate secondary MR progression.

  • Tertiary Prevention: Preventing complications and improving outcomes in patients with established MR.

    • Timely and appropriate intervention (surgical or transcatheter) for severe MR when indicated, based on symptoms, LV function, and other prognostic markers.
    • Ongoing optimal medical therapy for heart failure, arrhythmias (e.g., AF), and pulmonary hypertension.
    • Regular monitoring for recurrence of MR or development of complications.

Special Populations

  • Pediatric:

    • Etiology: Congenital MR (e.g., cleft mitral valve, parachute mitral valve, AV canal defects), rheumatic heart disease (more prevalent in developing countries), or MR secondary to cardiomyopathy.
    • Management: Often complex, requiring specialized pediatric cardiology and cardiac surgery expertise. Surgical repair is preferred to preserve future growth.

  • Geriatric:

    • Etiology: Degenerative MR (fibroelastic deficiency) is very common. Secondary MR due to ischemic or non-ischemic cardiomyopathy is also prevalent.
    • Challenges: Higher prevalence of comorbidities (CAD, CKD, frailty), which increase surgical risk. Careful risk assessment and consideration of transcatheter therapies (TMVr) are crucial. Decision-making is highly individualized. Asymptomatic severe MR may be more challenging to assess due to limited activity levels.

  • Pregnancy:

    • Physiological Changes: Increased blood volume, heart rate, and cardiac output, along with decreased systemic vascular resistance, can exacerbate MR and lead to symptoms of heart failure.
    • Management:
      • Mild to moderate MR is usually well-tolerated.
      • Severe MR carries higher risk of complications (heart failure, arrhythmias, adverse pregnancy outcomes).
      • Medical management (diuretics, vasodilators if necessary) is preferred. ACE inhibitors/ARBs are contraindicated. Beta-blockers are generally safe if needed for rate control or hypertension.
      • Surgical intervention during pregnancy is usually avoided unless life-threatening.
      • Careful obstetric and cardiology co-management is essential. Labor and delivery require close hemodynamic monitoring.

  • Comorbidities:

    • Coronary Artery Disease (CAD): Revascularization (CABG) should be considered, as it may improve secondary MR, especially in ischemic MR. If severe MR persists or is primary, concomitant mitral valve surgery is often performed.
    • Atrial Fibrillation (AF): Common. Management involves rate/rhythm control and anticoagulation (CHA2DS2-VASc score). MAZE procedure may be considered during valve surgery.
    • Chronic Kidney Disease (CKD): Increases surgical risk. Renal function must be closely monitored with diuretics and other medications. TMVr may be a more favorable option for high-risk CKD patients.
    • Pulmonary Hypertension: Indicates more advanced disease and higher risk. Often improves after successful MR correction.

Clinical Pearls

  • Diagnostic:

    • Auscultation is key: A holosystolic murmur radiating to the axilla is classic. However, in acute severe MR, the murmur may be soft or absent due to rapid equalization of LA-LV pressure.
    • Distinguish Primary vs. Secondary MR: Crucial for management. Echo findings (leaflet pathology vs. LV remodeling) are essential.
    • Don't rely solely on symptom status: Asymptomatic severe MR with LV dysfunction or other indicators (AF, PH) still warrants intervention.
    • Exercise echo can unmask symptoms/PH: For patients with discordant symptoms and resting echo findings.

  • Treatment:

    • Repair over Replacement for Primary MR: Always aim for valve repair in primary MR when feasible and durable, due to better outcomes and avoidance of anticoagulation.
    • Timing of Intervention is Critical: Especially in asymptomatic severe primary MR, waiting too long (e.g., LVEF <50% or LVESD >45mm) can lead to irreversible LV dysfunction. Follow guidelines strictly (LVEF <60% or LVESD >40mm are key thresholds).
    • GDMT is Foundational for Secondary MR: Aggressive optimization of medical therapy for heart failure is the first and most important step. TMVr is an adjunct for selected symptomatic patients on optimal GDMT.
    • Heart Team Approach: For complex cases, especially in determining surgical risk and suitability for transcatheter interventions, a multidisciplinary heart team discussion is vital.

  • Pitfalls:

    • Underestimation of Severity: Mild symptoms do not rule out severe MR, especially in sedentary patients. Rely on objective echo criteria.
    • Delaying Intervention: Waiting until severe LV dysfunction develops in primary MR.
    • Ignoring Pulmonary Hypertension: PH indicates more advanced disease and warrants careful consideration for intervention.
    • Inadequate GDMT for Secondary MR: Failing to optimize medical therapy before considering intervention.
    • Mistaking Functional MR for Primary MR: Misdiagnosis can lead to inappropriate interventions.

Recent Updates

  • Guidelines:
    • 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Emphasizes the importance of a heart team, detailed echo assessment, and refined indications for intervention, particularly for asymptomatic severe primary MR and the role of TMVr in secondary MR.
    • 2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease: Similar to ACC/AHA, with slightly different thresholds for LVESD in asymptomatic severe primary MR (LVESD ≥40-45mm). Stronger emphasis on TMVr for severe secondary MR in selected patients.
  • Evidence:
    • COAPT Trial (2018): Demonstrated that transcatheter mitral valve repair (TMVr) using the MitraClip device, when added to guideline-directed medical therapy, significantly reduced heart failure hospitalizations and mortality in symptomatic patients with severe secondary MR, LVEF 20-50%, and favorable anatomy. This study revolutionized the treatment of severe secondary MR.
    • MITRA-FR Trial (2018): Showed no benefit of TMVr over GDMT alone for severe secondary MR, highlighting the importance of patient selection, particularly the proportionality of MR to LV size. Patients in COAPT generally had more severe MR relative to their LV dilation.
  • Controversies:
    • Optimal Timing of Intervention in Asymptomatic Primary MR: While guidelines provide thresholds, the exact timing for intervention in patients with borderline LV function or only mild symptoms remains a topic of ongoing debate and depends on surgical risk and anticipated durability of repair.
    • Role of TMVr in Secondary MR: Despite COAPT, careful patient selection remains critical. Identifying which patients truly benefit is ongoing research, differentiating between "disproportionate" MR (where the valve lesion is a major contributor to symptoms) and "proportionate" MR (where the primary problem is global LV dysfunction).
    • Management of Moderate Secondary MR: Whether intervention for moderate secondary MR provides benefit is an area of active research.

Key References

  • Guidelines:

    • Otto, C. M., et al. (2021). 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 143(14), e72-e227.
    • Vahanian, A., et al. (2022). 2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. European Heart Journal, 43(7), 561-632.

  • Studies:

    • Stone, G. W., et al. (2018). Transcatheter Mitral-Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation. New England Journal of Medicine, 379(24), 2307-2318 (COAPT Trial).
    • Obadia, J. F., et al. (2018). Transcatheter Mitral-Valve Repair in Patients with Advanced Heart Failure and Secondary Mitral Regurgitation. New England Journal of Medicine, 379(24), 2297-2306 (MITRA-FR Trial).

  • Reviews:

    • Nishimura, R. A., & Vahanian, A. (2020). Mitral Regurgitation: Update on Diagnosis and Management. Circulation, 141(16), 1332-1342.
    • Carpentier, A. F. (1983). Cardiac Valve Surgery—The "French Correction". Journal of Thoracic and Cardiovascular Surgery, 86(3), 323-337 (Classic on valve classification and repair).

Dr. Vivek's AI | For Educational Purposes Only